DIABIMMUNE
Pathogenesis of Type 1 Diabetes - Testing the Hygiene Hypothesis
| Coordinatore | HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
| Nazionalità Coordinatore | Finland [FI] |
| Sito del progetto | http://www.diabimmune.org/ |
| Totale costo | 7˙697˙061 € |
| EC contributo | 5˙999˙900 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2014-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | coordinator | 0.00 |
| 2 |
Nome Ente NON disponibile
Organization address
address: STENBACKINKATU 9 contact info |
FI (HELSINKI) | participant | 0.00 |
| 3 |
"Ministry of Health and Social Development, Karelian Republic of the Russian Federation"
Organization address
address: "Lenin Street, 6" contact info |
RU (Petrozavodsk) | participant | 0.00 |
| 4 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 0.00 |
| 5 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 6 |
OU IMMUNOTRON
Organization address
address: Riia 185 contact info |
EE (TARTU) | participant | 0.00 |
| 7 |
Petrozavodsk State University
Organization address
address: LENIN STREET 33 33 contact info |
RU (PETROZAVODSK) | participant | 0.00 |
| 8 |
SIHTASUTUS TARTU UELIKOOLI KLIINIKUM
Organization address
address: PUUSEPA 1A contact info |
EE (TARTU) | participant | 0.00 |
| 9 |
TAMPEREEN YLIOPISTO
Organization address
address: Kalevantie 4 contact info |
FI (TAMPERE) | participant | 0.00 |
| 10 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 0.00 |
| 11 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 0.00 |
| 12 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Preliminary data indicate that there is a strong association between the incidence of immune-mediated diseases and improving standard of living and hygiene. One of the steepest gradient in standard of living worldwide is present at the border between Russian Karelia and Finland with a sevenfold difference in the gross national product, while Estonia represents a country in rapid transition. These three populations comprise a “living laboratory” providing a unique possibility to test the hygiene hypothesis in the development of immune-mediated diseases. The incidence of type 1 diabetes (T1D) is six times lower in Russian Karelia than in Finland, whereas there are very limited differences in the frequency of risk HLA genotypes in the background population. This proposal aims at comparing (i) the frequency of beta-cell autoimmunity and other organ-specific autoantibodies; (ii) the frequency of IgE-specific sensitisation and signs of allergy; (iii) the frequency of various infections; (iv) the gut microbial flora; and (v) dietary intake in young children between the three populations. The birth cohort arm of the study aims at (i) delineating the ontogeny of the immune system by using modern tools of functional genomics; (ii) comparing the functional characteristics of regulatory T cells; (iii) characterising the gut microbial colonisation in infants; (iv) assessing the timing of exposure to foreign proteins in infancy (v) defining the interrelations between dietary factors, gut microbial flora and acute microbial infections. The objectives will be approached by studying 1600 children at the age of 3 and 5 years and by observing a birth cohort comprising about 320 subjects with HLA-conferred susceptibility to autoimmunity from birth up to the age of 3 years in each country. This proposal is expected to provide new data on the reasons and mechanisms behind the increasing rates of T1D and other immune-mediated diseases seen in most developed countries after World War II.'